|
Match
|
Document |
Document Title |
|
|
US20110151005 |
METHODS AND MEANS FOR SOFT TISSUE ENGINEERING
Cellfree adipose tissue extracts, implants including the same and methods for the preparation thereof. The extracts and implants are capable of inducing adipogenesis and angiogenesis and are,... |
|
|
US20110311608 |
STABLE CHITOSAN HEMOSTATIC IMPLANT AND METHODS OF MANUFACTURE
Implantable hemostatic products with improved stability are prepared from crosslinked chitosan hemostatic compositions. The crosslinked chitosan hemostatic compositions have improved stability and... |
|
|
US20120148671 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. |
|
|
US20110002999 |
Biopolymer System for Tissue Sealing
A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix... |
|
|
US20120114754 |
RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient,... |
|
|
US20110229574 |
POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATION
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based... |
|
|
US20110142939 |
Use of a Combination of an Opioid Agonist and an Opioid Antagonist for the Treatment of Crohn's Disease and the Symptoms Associated with Crohn's Disease
The present invention is concerned with the use of combinations of opioid agonists and antagonists for treating Crohn's disease. |
|
|
US20130302420 |
OCULAR BIODEGRADABLE DRUG IMPLANT AND METHOD OF ITS USE
A biodegradable drug implant includes a PLG matrix and a non-steroid anti inflammation drug, for example diclofenac sodium. The implant is inserted into the eye in the anterior chamber, for... |
|
|
US20120294938 |
PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION
Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active... |
|
|
US20140294953 |
Abuse-Resistant Formulations
The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The... |
|
|
US20110020452 |
PROGENITOR CELL REPLICATION AND DIFFERENTIATION IN 3D
The present invention is directed to a new approach towards in situ differentiation of tissue progenitor cells, without the coventional requirements of weeks of cellular manipulation and... |
|
|
US20120231075 |
ABUSE-RESISTANT OPIOID DOSAGE FORM
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix. |
|
|
US20110020444 |
ABUSE-RESISTANT OPIOID DOSAGE FORM
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix. |
|
|
US20120282340 |
DRUG DELIVERY SYSTEM
The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain an Estrogen Receptor beta (ER-β) selective agonist. The wafers of the present... |
|
|
US20110236454 |
INJECTABLE DRUG DELIVERY FORMULATION
The invention provides an injectable formulation that includes an active agent; a biocompatible solvent system, crosslinkable polymers such as polysaccharides; and crosslinking agents; wherein the... |
|
|
US20120263788 |
CONTROLLED RELEASE HYDROCODONE FORMULATIONS
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,... |
|
|
US20100297239 |
OSSEOINTEGRATIVE MENISCUS AND CARTILAGE IMPLANTS BASED ON BETA-GLUCAN NANOCOMPOSITES
The present invention provides engineered composite materials for use in medical treatment of injured or degenerated menisci, cartilage, and bone. The composite materials include a cellulosic... |
|
|
US20110190688 |
Permeant Delivery System and Methods for Use Thereof
Disclosed are a patch, system, and method for delivery of a permeant composition into a subject via at least one formed pathway through a biological membrane of the subject. The patch comprises a... |
|
|
US20050158388 |
Treatment of gynecomastia with 4-hydroxy tamoxifen
The present invention provides methods for treating and preventing gynecomastia by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts,... |
|
|
US20150132360 |
MULTI-LAYERED ANTI-ADHESION DEVICE
Compositions and methods are provided for preparing an adhesion barrier in the form of a foldable or flexible biodegradable polymer matrix that effectively reduces, prevents or treats adhesions in... |
|
|
US20140199394 |
CONTROLLED RELEASE HYDROCODONE
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,... |
|
|
US20110052685 |
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHEN
Gastric retentive dosage forms for extended release of acetaminophen or for both immediate and extended release of acetaminophen are described. The dosage forms allow effective pain relief upon... |
|
|
US20110293720 |
PROGESTIN-CONTAINING DRUG DELIVERY SYSTEM
The present invention relates to drug delivery compositions in the form of thin water-soluble films (wafers), which contain small particles that comprise at least one progestin and at least one... |
|
|
US20110014290 |
SYSTEM AND METHOD FOR FACILITATING HEMOSTASIS WITH AN ABSORBABLE SPONGE
The present invention provides for a method and apparatus to provide hemostasis at a blood vessel puncture site, having a hemostasis material and a clot formation accelerator, wherein said clot... |
|
|
US20120107383 |
OSTEOCONDUCTIVE MATRICES COMPRISING CALCIUM PHOSPHATE PARTICLES AND STATINS AND METHODS OF USING THE SAME
Osteoconductive matrices and methods are provided that have one or more statins disposed in calcium phosphate particles. The matrices may be injected into a fracture site. The osteoconductive... |
|
|
US20110097405 |
ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM
The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain estradiol, or derivatives thereof, in low amounts. The wafers of the present... |
|
|
US20140134250 |
OXYMORPHONE CONTROLLED RELEASE FORMULATIONS
The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24... |
|
|
US20110117196 |
Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
The invention provides a novel solid pharmaceutical dosage form which includes an opiate, an opiate antagonist admixed with the analgetic (opiate agonist) and an amount of a hydrocolloid... |
|
|
US20130039981 |
Quick Dissolving, Long Acting Zinc Therapeutic Formulations
The present invention comprises a quick dissolving, long acting zinc therapeutic cold formulation containing high levels of an active compound encapsulated within bioadhesive/muco-adhesive... |
|
|
US20130171256 |
ALCOHOL-RESISTANT EXTENDED RELEASE DOSAGE FORMS COMPRISING VENLAFAXINE
This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically... |
|
|
US20140086988 |
Stabilized Protein Crystals, Formulations Containing Them and Methods of Making Them
This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention... |
|
|
US20050181057 |
Vaginal lubricant
A vaginal lubricant comprises (i) water, (ii) a DHEA salt, (iii) a polyether, and (iv) a lubricant. The pH of the vaginal lubricant is at least 5.6. |
|
|
US20140322327 |
DRUG DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF BIOACTIVE AGENTS
A drug delivery system for sustained delivery of bioactive agents, the system includes a matrix including nanofibrillated cellulose derived from plant based material and at least one bioactive... |
|
|
US20110104273 |
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF PHENYLEPHRINE
Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and... |
|
|
US20130202705 |
ALCOHOL-RESISTANT FORMULATIONS
This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose... |
|
|
US20120141583 |
ALCOHOL RESISTANT DOSAGE FORMS
Opioid controlled release formulation resistant to alcohol extraction of the opioid. |
|
|
US20130017264 |
ALGINATE TUBE DRUG DELIVERY SYSTEM AND METHOD THEREFOR
A drug delivery system which comprises alginate tube that is prepared by coating a substrate with alginate gel. One or more therapeutic drugs may also be present in the alginate gel or in the... |
|
|
US20110059162 |
TANNIN-CHITOSAN COMPOSITES
The invention provides a composition comprising a matrix of chitosan and a tannin wherein the chitosan is electrostatically bonded to the tannin to form a chitosan-tannin composite material. The... |
|
|
US20110097408 |
CHITOSAN-BASED MATRICES AND USES THEREOF
This invention relates a controlled release delivery composition for an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and... |
|
|
US20110129536 |
NANOCOMPOSITE MATERIALS BASED ON METALLIC NANOPARTICLES STABILIZED WITH BRANCHED POLYSACCHARIDES
The present invention provides nanocomposite systems made of metallic nanoparticles stabilized with branched cationic polysaccharides, in particular alditolic or aldonic mono- and... |
|
|
US20110027361 |
EXTENDED RELEASE DOSAGE FORM OF PALIPERIDONE
The present invention relates to an extended release solid oral pharmaceutical composition comprising Paliperidone or its pharmaceutically acceptable salts and process for preparing the same. |
|
|
US20130045162 |
DELIVERY SYSTEM FOR SPECIFICALLY TARGETING CANCER CELLS AND METHOD OF USE THEREOF
Methods for prevention, treatment or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a... |
|
|
US20110111033 |
HYDROGEL WITH COVALENTLY CROSSLINKED CORE
A novel hydrogel system is provided. The hydrogel system comprises a biocompatible hydrogel core having dispersed therein a covalently crosslinked polymer matrix. The hydrogel system is useful per... |
|
|
US20150157577 |
MATRIX AND LAYER COMPOSITIONS FOR PROTECTION OF BIOACTIVES
The invention relates to matrix and layer compositions comprising a first polymer. The matrix and layer compositions are useful in the delivery of bioactives. In particular, the matrices and... |
|
|
US20110189292 |
DERMAL FILLERS COMPRISING SILK FIBROIN HYDROGELS AND USES THEREOF
The present specification provides compositions useful as dermal fillers and methods using such compositions to treat a condition of skin. |
|
|
US20110171311 |
STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES
The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. |
|
|
US20150118295 |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including... |
|
|
US20120009263 |
GRANULAR DELIVERY SYSTEM
A granular delivery system and a method of preparing the same by creating a melt emulsion having a continuous phase and a dispersed active, wherein the continuous phase includes trehalose and a... |
|
|
US20110244032 |
DISPERSIBLE PHOSPHOLIPID STABILIZED MICROPARTICLES
Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of... |
|
|
US20130189333 |
ORAL PRODUCT
An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an... |